SABS · SAB Biotherapeutics, Inc.

Summary

SAB Biotherapeutics, Inc. furnished additional data from its Phase 1 clinical trial of HUman anti-thymocyte biologic under Item 7.01 via Exhibits 99.1 and 99.2, and announced this under Item 8.01 on March 10, 2026. The press release in Exhibit 99.1 details the first-in-human trial results.

Key takeaways

• Announcement date: March 10, 2026
• Phase 1 clinical trial data released
• Product: HUman anti-thymocyte biologic
• First-in-human (HUMAN) trial
• Exhibits 99.1 (Press Release) and 99.2 furnished